RNA Atrium Therapeutics, Inc.

NASDAQ
$12.84

Atrium Therapeutics, Inc. (RNA) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $2.31 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +5.2% since its last earnings release on August 13, 2026.

Atrium Therapeutics Reported Earnings
Thursday, August 13, 2026 · 4:44 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 12
Thursday · 4:40 PM ET
Earnings Whisper
-
vs ($2.31)
Rev est $19.64M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $12.84

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Atrium Therapeutics, Inc.

Avidity Biosciences Inc. is a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates(TM). The company's AOC platform design, engineer and develop therapeutics which combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies. Its lead product candidate consist AOC 1001, is designed to treat myotonic dystrophy type 1,and other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. Avidity Biosciences Inc. is based in SAN DIEGO.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Held By 2 ETFs, by dollar flow